Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

TScan Therapeutics (United States) | Researchclopedia

Back to institutions

TScan Therapeutics (United States)

Waltham, Massachusettscompany

67

Works

11,523

Citations

38

h-index

Top Research Topics

CAR-T cell therapy research Immunotherapy and Immune Responses Monoclonal and Polyclonal Antibodies Research

Top Researchers

Andrew Spencer The Alfred Hospital

839 works34,381 citationsh-index: 80

Recent Research

Abstract PR001: Exploiting HIF-driven endogenous retroviral neoantigens to advance kidney cancer immunotherapy

Qinqin Jiang,David A. Braun,et al.

20260 citations

Hematopoietic Stem Cell Transplantation

Cancer Immunotherapy and Biomarkers

Acute Lymphoblastic Leukemia research

T-cell and B-cell Immunology

SARS-CoV-2 and COVID-19 Research

RNA and protein synthesis mechanisms

Cell Adhesion Molecules Research

Biosimilars and Bioanalytical Methods

vaccines and immunoinformatics approaches

Salvador Martı́nez Universidad Popular Autónoma del Estado de Puebla

400 works18,745 citationsh-index: 71

J. A. H. Murray North Bristol NHS Trust

559 works17,948 citationsh-index: 74

Alexandra J. Spencer University of Oxford

116 works15,177 citationsh-index: 36

Yifan Wang Huazhong Agricultural University

436 works11,860 citationsh-index: 48

Yun Wang Shenyang Medical College

502 works11,808 citationsh-index: 54

TSC-101 Eliminates Recipient Hematopoietic Cells and Demonstrates Potential for Improved Relapse-Free Survival in Patients with AML, ALL, or MDS Undergoing Allogeneic HCT (allo-HCT) with Reduced Intensity Conditioning (RIC): Updated Results from the Phase 1 (ALLOHA) Trial

Monzr M. Al Malki,Yi-Bin Chen,et al.

20260 citations

P0023 Anti-TL1A and anti-IL-23 combination therapy is superior to its constituent monotherapies in mouse anti-CD40 colitis

M Siegel,D Giles,et al.

20260 citations

DF6215, an α-optimized IL-2-Fc fusion, expands immune effectors and drives robust preclinical anti-tumor activity

Adam Stockmann,Sylvia Vincent,et al.

20250 citations

Trials in progress: Design of a registrational Phase 2 trial (ALLOHA) using an external control arm for TSC-101 for prevention of relapse post allogeneic HCT in patients with ALL, AML, or MDS

Monzr M. Al Malki,Yi-Bin Chen,et al.

20250 citations

TSC-101 eliminates recipient hematopoietic cells and demonstrates potential for improved relapse-free survival in patients with AML, ALL, or MDS undergoing allogeneic HCT: Updated results from the Phase 1 (ALLOHA) trial

Monzr M. Al Malki,Yi-Bin Chen,et al.

20250 citations